[go: up one dir, main page]

SG11201703237VA - Humanized tau antibodies in alzheimer's disease - Google Patents

Humanized tau antibodies in alzheimer's disease

Info

Publication number
SG11201703237VA
SG11201703237VA SG11201703237VA SG11201703237VA SG11201703237VA SG 11201703237V A SG11201703237V A SG 11201703237VA SG 11201703237V A SG11201703237V A SG 11201703237VA SG 11201703237V A SG11201703237V A SG 11201703237VA SG 11201703237V A SG11201703237V A SG 11201703237VA
Authority
SG
Singapore
Prior art keywords
alzheimer
disease
tau antibodies
humanized tau
humanized
Prior art date
Application number
SG11201703237VA
Inventor
Michal Novak
Eva Kontsekova
Branislav Kovacech
Rostislav Skrabana
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of SG11201703237VA publication Critical patent/SG11201703237VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
SG11201703237VA 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease SG11201703237VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462081809P 2014-11-19 2014-11-19
PCT/IB2015/002610 WO2016079597A1 (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease

Publications (1)

Publication Number Publication Date
SG11201703237VA true SG11201703237VA (en) 2017-06-29

Family

ID=55411706

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703237VA SG11201703237VA (en) 2014-11-19 2015-11-18 Humanized tau antibodies in alzheimer's disease

Country Status (24)

Country Link
US (3) US10160799B2 (en)
EP (2) EP3221349B1 (en)
JP (3) JP6830061B2 (en)
KR (1) KR20170126855A (en)
CN (1) CN107428820B (en)
AU (2) AU2015348012B2 (en)
BR (1) BR112017010498A2 (en)
CA (1) CA2966964A1 (en)
CY (1) CY1123746T1 (en)
DK (1) DK3221349T3 (en)
ES (1) ES2848376T3 (en)
HR (1) HRP20210124T1 (en)
HU (1) HUE053239T2 (en)
IL (2) IL251921B (en)
LT (1) LT3221349T (en)
MX (2) MX388142B (en)
PL (1) PL3221349T3 (en)
PT (1) PT3221349T (en)
RS (1) RS61431B1 (en)
RU (2) RU2020126237A (en)
SG (1) SG11201703237VA (en)
SI (1) SI3221349T1 (en)
SM (1) SMT202100055T1 (en)
WO (1) WO2016079597A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24446B1 (en) 2013-03-13 2019-10-04 Prothena Biosciences Ltd A HUMANIZED MONOCLONAL ANTIBODY JOINING TAU
MX2017005834A (en) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease.
SG11201703237VA (en) * 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
MY197413A (en) * 2016-05-02 2023-06-16 Prothena Biosciences Ltd Antibodies recognizing tau
BR112018072389A2 (en) * 2016-05-02 2019-02-19 Prothena Biosciences Limited antibodies that recognize tau
PL3452507T3 (en) 2016-05-02 2023-01-09 Prothena Biosciences Limited Tau immunotherapy
CN110520440A (en) 2017-02-17 2019-11-29 戴纳立制药公司 Anti- τ antibody and its application method
CA3056517A1 (en) * 2017-03-28 2018-10-04 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
BR112019022906A2 (en) 2017-05-02 2020-05-26 Prothena Biosciences Limited ANTIBODIES THAT RECOGNIZE TAU
JOP20190269A1 (en) 2017-06-15 2019-11-20 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. CANCER TREATMENT BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
WO2019048017A1 (en) * 2017-09-07 2019-03-14 Danmarks Tekniske Universitet Methods for removing nox from a gas stream containing more than one gaseous compound
TWI809562B (en) 2017-10-16 2023-07-21 日商衛材R&D企管股份有限公司 Anti-tau antibodies and uses thereof
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
US12398201B2 (en) 2018-02-19 2025-08-26 New York University Tau single domain antibodies
RU2020135052A (en) 2018-03-28 2022-04-29 Аксон Ньюросайенс Се METHODS FOR DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE BASED ON ANTIBODIES
KR20250048591A (en) * 2018-05-03 2025-04-09 워싱턴 유니버시티 Methods of diagnosing and treating based on site-specific tau phosphorylation
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
WO2020077380A1 (en) * 2018-10-17 2020-04-23 The University Of Queensland Methods and compositions for treating tauopathies
WO2020097561A1 (en) * 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
CN120058944A (en) 2019-01-30 2025-05-30 真和制药有限公司 Anti-GAL3 antibodies and uses thereof
CU20210073A7 (en) 2019-03-03 2022-04-07 Prothena Biosciences Ltd ANTIBODIES THAT BIND WITHIN THE CDRS-DEFINED MICROTUBULE-BINDING REGION OF TAU
TWI877179B (en) * 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 Anti-angpt2 antibodies
EP4013772A4 (en) * 2019-08-13 2024-06-05 Washington University METHODS FOR DETECTING TAU ISOFORMS OF MTBR AND THEIR USE
CA3150156A1 (en) 2019-09-09 2021-03-18 Michal Novak BIOMARKERS AND TREATMENTS FOR ALZHEIMER'S DISEASE AND MILD COGNITIVE DISORDER
EP4028775A4 (en) 2019-09-10 2023-04-12 Washington University Blood-based assay for diagnosing and treating based on site-specific tau phosphorylation
JP2023506014A (en) * 2019-12-12 2023-02-14 アレクトル エルエルシー Methods of using anti-CD33 antibodies
WO2021173962A1 (en) * 2020-02-28 2021-09-02 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
MX2022014786A (en) 2020-05-26 2023-01-16 Truebinding Inc Methods of treating inflammatory diseases by blocking galectin-3.
MX2023003334A (en) * 2020-09-22 2023-05-30 Kathleen E Clarence Smith Pharmaceutical combination for the treatment of human hypocholinergic disorders.
CN112625129B (en) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 A kind of anti-human interleukin 23 and test kit comprising same and detection method thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2023163821A (en) * 2022-04-28 2023-11-10 国立大学法人鳥取大学 Diagnostic markers for progressive supranuclear palsy
KR20250044781A (en) * 2022-08-10 2025-04-01 주식회사 엔케이맥스 Treatment of Alzheimer's disease using expanded natural killer cells
JP2025535203A (en) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド Tau-binding compounds
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech, Inc. New uses of omalizumab
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2026005695A1 (en) * 2024-06-25 2026-01-02 Islam Tohidul Detection of oligomeric tau and soluble tau aggregates

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HU196394B (en) 1986-06-27 1988-11-28 Richter Gedeon Vegyeszet Process for preparing 2-halogenated ergoline derivatives
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE69328430T2 (en) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer TARGETED LIPOSOME TO THE BLOOD BRAIN CABINET
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
CU22615A1 (en) 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
CA2142190C (en) 1995-02-14 1998-01-27 Marc Lessard Waste air exfiltration duct
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
WO1997023243A1 (en) 1995-12-22 1997-07-03 Bristol-Myers Squibb Company Branched hydrazone linkers
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
ATE319745T1 (en) 1997-05-21 2006-03-15 Biovation Ltd METHOD FOR PRODUCING NON-IMMUNOGENIC PROTEINS
ES2244066T3 (en) 1997-06-24 2005-12-01 Genentech, Inc. PROCEDURE AND COMPOSITIONS OF GALACTOSILATED GLICOPROTEINS.
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
EP1214598B1 (en) 1999-09-09 2006-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening for inhibitors of "paired helical filaments"
DE1257584T1 (en) 2000-02-24 2003-05-28 Lilly Co Eli HUMANIZED ANTIBODIES THAT DETECT AMYLOID BETA PEPTID
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (en) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation
ATE445838T1 (en) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc COMPOSITIONS AND METHODS FOR MODULATING TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
DE60320258T2 (en) 2002-07-12 2009-06-25 Axon Neuroscience Forschungs- Und Entwicklungs Gmbh TRANSGENIC ANIMAL EXPRESSING THE TRUNKED ALZHEIMER TAU PROTEIN
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003302676A1 (en) 2002-12-03 2004-06-23 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
AU2003291910B2 (en) 2002-12-24 2009-10-01 Bellus Health (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
PT2489364E (en) 2003-11-06 2015-04-16 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP6371526B2 (en) * 2010-10-07 2018-08-08 エーシー イミューン エス．エー． Phosphorylated site-specific antibody that recognizes tau
AU2011315181B2 (en) * 2010-10-11 2016-07-28 Biogen International Neuroscience Gmbh Human anti-tau antibodies
SG11201400125RA (en) 2011-09-19 2014-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
MX356800B (en) 2012-04-05 2018-06-13 Ac Immune Sa Humanized tau antibody.
HRP20201422T1 (en) * 2012-12-21 2021-02-19 Biogen Ma Inc. Human anti-tau antibodies
SG11201703237VA (en) * 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease

Also Published As

Publication number Publication date
US10160799B2 (en) 2018-12-25
WO2016079597A8 (en) 2020-07-02
PT3221349T (en) 2021-01-21
CY1123746T1 (en) 2022-05-27
WO2016079597A1 (en) 2016-05-26
MX2021014367A (en) 2022-01-06
JP6864763B2 (en) 2021-04-28
JP2021119774A (en) 2021-08-19
US20180142007A1 (en) 2018-05-24
AU2015348012A1 (en) 2017-05-18
RU2730668C2 (en) 2020-08-24
AU2020227007B2 (en) 2024-05-30
US11319363B2 (en) 2022-05-03
LT3221349T (en) 2021-02-10
RS61431B1 (en) 2021-03-31
ES2848376T3 (en) 2021-08-09
EP3786182A1 (en) 2021-03-03
DK3221349T3 (en) 2021-01-04
MX388142B (en) 2025-03-19
RU2017120688A (en) 2018-12-19
HUE053239T2 (en) 2021-06-28
RU2020126237A (en) 2020-12-01
US10745469B2 (en) 2020-08-18
MX2017006663A (en) 2017-08-21
IL251921B (en) 2021-07-29
RU2017120688A3 (en) 2019-07-17
HK1244495A1 (en) 2018-08-10
JP6830061B2 (en) 2021-02-17
US20210009666A1 (en) 2021-01-14
CN107428820B (en) 2022-03-22
AU2020227007A1 (en) 2020-09-17
AU2015348012B2 (en) 2020-07-02
BR112017010498A2 (en) 2017-12-26
IL251921A0 (en) 2017-06-29
JP2020141669A (en) 2020-09-10
EP3221349B1 (en) 2020-11-04
CA2966964A1 (en) 2016-05-26
SI3221349T1 (en) 2021-02-26
US20190169276A1 (en) 2019-06-06
IL284250A (en) 2021-07-29
CN107428820A (en) 2017-12-01
PL3221349T3 (en) 2021-05-17
EP3221349A1 (en) 2017-09-27
KR20170126855A (en) 2017-11-20
SMT202100055T1 (en) 2021-03-15
HRP20210124T1 (en) 2021-03-19
JP2018502558A (en) 2018-02-01

Similar Documents

Publication Publication Date Title
IL284250A (en) Humanized tau antibodies in alzheimer's disease
IL324723A (en) Methods for treating alzheimer's disease
ZA201900373B (en) Anti-tim-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
IL252929A0 (en) Humanized anti-acth antibodies and use thereof
GB201610044D0 (en) Antibodies
IL251837A0 (en) Anti-endoglin antibodies and uses thereof
LT3452513T (en) Humanized anti-il-1r3 antibodies
PL3311171T3 (en) Antibody epitope
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
PT3101132T (en) Anti-transthyretin human antibody
GB201603291D0 (en) Antibodies
GB201512596D0 (en) Biomolecules involved in Alzheimer's disease
PL3180356T3 (en) Human anti-fgfr4 antibody
IL267271A (en) Anti-il-5 antibodies
PT3484921T (en) Anti-il-22r antibodies
SG11201610594WA (en) Anti-il4-il 13 bispecific antibodies
IL260083B1 (en) Anti-myl9 antibody
SG11201703292VA (en) ANTI HUMAN Gas6 MONOCLONAL ANTIBODY
IL272676B (en) Anti-il4-il 13 bispecific antibodies
GB201621907D0 (en) Antibody epitope
GB201414038D0 (en) Alzheimer's disease
GB201622197D0 (en) Antibodies